Literature DB >> 19148933

Familial interstitial disease with I73T mutation: A mid- and long-term study.

Rola Abou Taam1, Francis Jaubert, Sophie Emond, Muriel Le Bourgeois, Ralph Epaud, Chantal Karila, Delphine Feldmann, Pierre Scheinmann, Jacques de Blic.   

Abstract

OBJECTIVES: To describe the long-term course and the management in children of chronic interstitial lung disease associated with I73T mutation.
MATERIALS AND METHODS: Clinical, radiological, and histological data from one family including five children and two adults were analyzed retrospectively for three patients and prospectively for the others.
RESULTS: Mean age of onset of respiratory symptoms for children was 6 months (2-15 months). The follow up was 14 months to 15 years (mean 55 months). The children were treated by intravenous high dose methylprednisolone pulses (6-15, mean 12). Four received oral prednisolone (mean 16 months) and hydroxychloroquine, one of these had additional mycophenolate mofetil. One adult with mild respiratory symptoms in infancy and another who was symptom free were also diagnosed. Both of them received no treatment. BAL fluids were obtained in all children: pro-SPC and SPB were positive in all. Lung biopsies were performed in two children respectively at 7 months, showing interstitial pneumonia features with endoluminal macrophage and type II alveolar cells hyperplasia, and at 33 months, showing subpleural microbullae, areas of interstitial pneumonia and type II alveolar cells hyperplasia. Immunohistochemistry showed for both an increased SPB and TTF1 staining in type II cells nuclei and a faint staining for pro-SPC and for ABCA3. Genetic diagnosis obviated the need for biopsy in other cases. The clinical status progressively improved and oxygen supplementation could be stopped after 3-14 months (mean 9 months). The CT scans initially showed ground glass opacities, then reduction in the ground glass pattern associated with clinical improvement and development of cysts.
CONCLUSION: This kindred illustrates the variability of respiratory involvement and prognosis. It confirms the value of genetic screening for surfactant protein genes mutations. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148933     DOI: 10.1002/ppul.20970

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  28 in total

1.  Chronic ventilation in infants with surfactant protein C mutations: an alternative to lung transplantation.

Authors:  Deborah R Liptzin; Tarak Patel; Robin R Deterding
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

2.  Epithelial Expression of an Interstitial Lung Disease-Associated Mutation in Surfactant Protein-C Modulates Recruitment and Activation of Key Myeloid Cell Populations in Mice.

Authors:  Alessandro Venosa; Jeremy Katzen; Yaniv Tomer; Meghan Kopp; Sarita Jamil; Scott J Russo; Surafel Mulugeta; Michael F Beers
Journal:  J Immunol       Date:  2019-03-25       Impact factor: 5.422

3.  Clinical and ultrastructural spectrum of diffuse lung disease associated with surfactant protein C mutations.

Authors:  Donatella Peca; Renata Boldrini; Jan Johannson; Joseph T Shieh; Arianna Citti; Stefania Petrini; Teresa Salerno; Salvatore Cazzato; Raffaele Testa; Francesco Messina; Alfredo Onofri; Giovanna Cenacchi; Per Westermark; Nicola Ullmann; Nicola Ullman; Paola Cogo; Renato Cutrera; Olivier Danhaive
Journal:  Eur J Hum Genet       Date:  2015-03-18       Impact factor: 4.246

4.  Outcomes of Lung Transplantation for Infants and Children with Genetic Disorders of Surfactant Metabolism.

Authors:  Whitney B Eldridge; Qunyuan Zhang; Albert Faro; Stuart C Sweet; Pirooz Eghtesady; Aaron Hamvas; F Sessions Cole; Jennifer A Wambach
Journal:  J Pediatr       Date:  2017-02-16       Impact factor: 4.406

5.  MUC5B expression and location in surfactant protein C mutations in children.

Authors:  Deborah R Liptzin; Alan M Watson; Elissa Murphy; Miranda E Kroehl; Megan K Dishop; Csaba Galambos; Christopher M Evans; Marvin I Schwarz; Robin R Deterding; David A Schwartz
Journal:  Pediatr Pulmonol       Date:  2015-04-07

6.  A nonaggregating surfactant protein C mutant is misdirected to early endosomes and disrupts phospholipid recycling.

Authors:  Michael F Beers; Arie Hawkins; Jean Ann Maguire; Adam Kotorashvili; Ming Zhao; Jennifer L Newitt; Wenge Ding; Scott Russo; Susan Guttentag; Linda Gonzales; Surafel Mulugeta
Journal:  Traffic       Date:  2011-06-28       Impact factor: 6.215

Review 7.  Pulmonary fibrosis in the era of stratified medicine.

Authors:  Susan K Mathai; Chad A Newton; David A Schwartz; Christine Kim Garcia
Journal:  Thorax       Date:  2016-10-31       Impact factor: 9.139

8.  Revealing the Secrets of Idiopathic Pulmonary Fibrosis.

Authors:  Richard K Albert; David A Schwartz
Journal:  N Engl J Med       Date:  2019-01-03       Impact factor: 91.245

9.  A non-BRICHOS surfactant protein c mutation disrupts epithelial cell function and intercellular signaling.

Authors:  Markus Woischnik; Christiane Sparr; Sunčana Kern; Tobias Thurm; Andreas Hector; Dominik Hartl; Gerhard Liebisch; Surafel Mulugeta; Michael F Beers; Gerd Schmitz; Matthias Griese
Journal:  BMC Cell Biol       Date:  2010-11-20       Impact factor: 4.241

10.  Persistent Lung Disease in Adults with NKX2.1 Mutation and Familial Neuroendocrine Cell Hyperplasia of Infancy.

Authors:  Rebekah J Nevel; Errine T Garnett; John A Worrell; Ronald L Morton; Lawrence M Nogee; Timothy S Blackwell; Lisa R Young
Journal:  Ann Am Thorac Soc       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.